Skip to main content
. 2022 May 12;28(14):3127–3140. doi: 10.1158/1078-0432.CCR-21-4289

Figure 6.

Figure 6. PAM50 subtypes associate with prostate cancer treatment outcomes in men with mCRPC. A and B, PAM50 subtype associates with overall survival after the initiation of first-line AR signaling inhibitors and time on treatment by Kaplan–Meier analysis in the SU2C cohort. Number of samples, overall and pairwise log-rank test P values are indicated on plots. C, Gene expression microarray-based PAM50 classifications of multiple tumors from patients with mCRPC. Tumor counts are the number of tumors evaluated per individual patient. Colors reflect PAM50 classification and shading reflects the confidence of the PAM50 allocation based on the output of the PAM50 algorithm. D, Association of PAM50 subtype and time on docetaxel chemotherapy in the UW rapid autopsy cohort (overall and pairwise log-rank P values shown on plot). E, Association of PAM50 subtype and time on docetaxel chemotherapy in the UW rapid autopsy cohort in patients with concordant PAM50 tumor classifications and LumA and LumB tumors combined into a single luminal tumor category (P = 0.03 by log-rank test; A, B, D, and E). Number of samples are indicated on plots.

PAM50 subtypes associate with prostate cancer treatment outcomes in men with mCRPC. A and B, PAM50 subtype associates with overall survival after the initiation of first-line AR signaling inhibitors and time on treatment by Kaplan–Meier analysis in the SU2C cohort. Number of samples, overall and pairwise log-rank test P values are indicated on plots. C, Gene expression microarray-based PAM50 classifications of multiple tumors from patients with mCRPC. Tumor counts are the number of tumors evaluated per individual patient. Colors reflect PAM50 classification and shading reflects the confidence of the PAM50 allocation based on the output of the PAM50 algorithm. D, Association of PAM50 subtype and time on docetaxel chemotherapy in the UW rapid autopsy cohort (overall and pairwise log-rank P values shown on plot). E, Association of PAM50 subtype and time on docetaxel chemotherapy in the UW rapid autopsy cohort in patients with concordant PAM50 tumor classifications and LumA and LumB tumors combined into a single luminal tumor category (P = 0.03 by log-rank test; A, B, D, and E). Number of samples are indicated on plots.